Phys Written Answers · endocrine
Multiple Endocrine Neoplasia — Written Clinical Reasoning
DCE-style written reasoning for Multiple Endocrine Neoplasia.
1 min readVerification in progress
On this page
Study tools
Target exams
FRACP DCEMRCP Part 2
Prompt
DCE-style written reasoning for Multiple Endocrine Neoplasia.
SAQ 1 — Integrated plan (12 marks)
Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]
Model Answer
1. Frame and red flags (3 marks) [1]
State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]
2. Discriminating assessment (3 marks) [2]
List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]
3. Treatment sequence (4 marks) [1] [3]
Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]
4. Follow-up and communication (2 marks) [2]
Disposition, safety-net advice, and who owns follow-up. [1] [2]
References6ShowHide
- [1]Thelen AE, Hogan EM, Su MW, McHenry CR The Genetics of Familial Neoplastic Thyroid Disease and Primary Hyperparathyroidism Surg Clin North Am, 2026.PMID 42419309
- [2]Noso S, Miki H, Hiromine Y, Babaya N, et al. Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature Endocr J, 2026.PMID 42324136
- [3]Nosé V, Canberk S, Baloch Z Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management Adv Anat Pathol, 2026.PMID 42319956
- [4]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
- [5]Mariën L, Chhajlani S, De Herdt C, Ceulemans K, et al. Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence J Neuroendocrinol, 2026.PMID 42140697
- [6]Moura MJ, Chatterjee A, Wali S, Garza DR, et al. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review Expert Opin Drug Saf, 2026.PMID 41995025